The role of PTEN signaling perturbations in cancer and in targeted therapy

Oncogene

Volumn 27, Issue 41, 2008, Pages 5477-5485

  Keniry, M ^a   Parsons, R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

AKT; PI3K; PTEN; Targeted chemotherapy

Indexed keywords

CETUXIMAB; GEFITINIB; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; AUTISM; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL AGING; CELL CYCLE PROGRESSION; CELL POLARITY; CELL PROLIFERATION; CHEMOTAXIS; COLORECTAL CANCER; CORRELATION ANALYSIS; DIABETES MELLITUS; DNA DAMAGE; GENE DELETION; GENE MUTATION; HOMOZYGOSITY; HUMAN; MUSCLE CONTRACTILITY; NEOPLASM; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 51849097348     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.248     Document Type: Review

References (140)

1. Accili D, Arden KC. (2004). FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117: 421-426.
2. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. (1996). Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399: 333-338.
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
4. Ali IU, Schriml LM, Dean M. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932.
5. Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC. (1989). PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57: 167-175.
6. Baker SJ. (2007). PTEN enters the nuclear age. Cell 128: 25-28.
7. Barr FG. (2001). Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20: 5736-5746.
8. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. (2005). Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 15: 1839-1846.
9. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285.
10. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
11. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. (1998). Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123-127.
12. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG et al. (1998). Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16: 3215-3218.
13. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al. (1997). Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000.
14. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
15. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
16. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. (2008). PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 28: 3281-3289.
17. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X et al. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 20: 1569-1574.
18. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G. (1998). PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16: 541-545.
19. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
20. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP et al. (1999). Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337(Part 3): 575-583.
21. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T et al. (1997). Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710-4713.
22. Das S, Dixon JE, Cho W. (2003). Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA 100: 7491-7496.
23. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
24. Deleris P, Gayral S, Breton-Douillon M. (2006). Nuclear Ptdlns(3,4,5)P3 signaling: an ongoing story. J Cell Biochem 98: 469-485.
25. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222-224.
26. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355.
27. Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD et al. (2008). Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68: 2122-2131.
28. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN et al. (1998). PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259-2264.
29. Fang X, Yu S, Eder A, Mao M, Bast Jr RC, Boyd D et al. (1999). Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18: 6635-6640.
30. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743-1748.
31. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. (2002). Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487.
32. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M et al. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
33. Frech M, Andjelkovic M, Ingley E, Reddy KK, Falck JR, Hemmings BA. (1997). High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem 272: 8474-8481.
34. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3: 117-130.
35. Fukuyama M, Rougvie AE, Rothman JH. (2006). C elegans DAF- 18/PTEN mediates nutrient-dependent arrest of cell cycle and growth in the germline. Curr Biol 6: 773-779.
36. Furnari FB, Huang HJ, Cavenee WK. (1998). The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58: 5002-5008.
37. Furnari FB, Lin H, Huang HS, Cavenee WK. (1997). Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94: 12479-12484.
38. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. (1999). The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96: 10182-10187.
39. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. (2000). Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 60: 7033-7038.
40. Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J et al. (2006). Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 17: 4002-4013.
41. Goberdhan DC, Paricio N, Goodman EC, Mlodzik M, Wilson C. (1999). Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev 13: 3244-3258.
42. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y et al. (2005). Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33-44.
43. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
44. Hwangbo DS, Gershman B, Tu MP, Palmer M, Tatar M. (2004). Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429: 562-566.
45. Iijima M, Devreotes P. (2002). Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 109: 599-610.
46. Iijima M, Huang YE, Devreotes P. (2002). Temporal and spatial regulation of chemotaxis. Dev Cell 3: 469-478.
47. Janetopoulos C, Borleis J, Vazquez F, Iijima M, Devreotes P. (2005). Temporal and spatial regulation of phosphoinositide signaling mediates cytokinesis. Dev Cell 8: 467-477.
48. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS et al. (2008). PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
49. Keller C, Hansen MS, Coffin CM, Capecchi MR. (2004). Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18: 2608-2613.
50. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM et al. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99: 2884-2889.
51. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC et al. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273.
52. Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W et al. (2005). FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2: 153-163.
53. Klarlund JK, Guilherme A, Holik JJ, Virbasius JV, Chawla A, Czech MP. (1997). Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 275: 1927-1930.
54. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A. (1996). Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 16: 5905-5914.
55. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K et al. (2005). Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92: 1711-1719.
56. Laffargue M, Raynal P, Yart A, Peres C, Wetzker R, Roche S et al. (1999). An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid. J Biol Chem 274: 32835-32841.
57. Lagutina I, Conway SJ, Sublett J, Grosveld GC. (2002). Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol 22: 7204-7216.
58. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. (2002). Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342.
59. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. (2003). Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 22: 5501-5510.
60. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. (2006). Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 23: 575-587.
61. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
62. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N et al. (1998). The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58: 5667-5672.
63. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160.
64. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67.
65. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
66. Lin WM, Forgacs E, Warshal DP, Yeh IT, Martin JS, Ashfaq R et al. (1998). Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 4: 2577-2583.
67. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A et al. (2006). Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119: 5160-5168.
68. Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. (2005a). PTEN enters the nucleus by diffusion. J Cell Biochem 96: 221-234.
69. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. (2005b). Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 25: 6211-6224.
70. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. (2005). Rheb binds and regulates the mTOR kinase. Curr Biol 15: 702-713.
71. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. (2005a). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
72. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O et al. (2005b). Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19: 1779-1786.
73. Maehama T, Dixon JE. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
74. Manning BD, Cantley LC. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
75. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162.
76. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ et al. (1997). Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16: 333-334.
77. Moasser MM. (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487.
78. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518.
79. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
80. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. (2000). Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982.
81. Ogg S, Ruvkun G. (1998). The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell 2: 887-893.
82. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. (2006). PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568.
83. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani Met al. (2007). Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210.
84. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
85. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L et al. (2005). Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
86. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96: 1563-1568.
87. Potter CJ, Pedraza LG, Xu T. (2002). Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658-665.
88. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L et al. (2005). Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7: 193-204.
89. Puc J, Parsons R. (2005). PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 4: 927-929.
90. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92: 11746-11750.
91. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM et al. (1999). Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110-2115.
92. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS et al. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187-4190.
93. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R et al. (2000). 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 31: 504-508.
94. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J et al. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40: 102-107.
95. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
96. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M et al. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104: 7564-7569.
97. Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
98. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
99. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
100. Sasaki AT, Janetopoulos C, Lee S, Charest PG, Takeda K, Sundheimer LW et al. (2007). G protein-independent Ras/PI3K/F-actin circuit regulates basic cell motility. J Cell Biol 178: 185-191.
101. Serunian LA, Auger KR, Roberts TM, Cantley LC. (1990). Production of novel polyphosphoinositides in vivo is linked to cell transformation by polyomavirus middle T antigen. J Virol 64: 4718-4725.
102. Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG et al. (1998). Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 77: 684-688.
103. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. (2005). The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
104. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP et al. (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170.
105. Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fischer R, Drepps A et al. (1991). Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65: 83-90.
106. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM et al. (2002). PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children0s oncology group. J Clin Oncol 20: 2672-2679.
107. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y et al. (2001). Regulation of PTEN transcription by p53. Mol Cell 8: 317-325.
108. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
109. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
110. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF et al. (1997). Dual role of phosphatidylinositol-3,4, 5-trisphosphate in the activation of protein kinase B. Science 277: 567-570.
111. Tanaka K, Horiguchi K, Yoshida T, Takeda M, Fujisawa H, Takeuchi K et al. (1999). Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus. J Biol Chem 274: 3919-3922.
112. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI et al. (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940.
113. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99: 13571-13576.
114. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13: 1259-1268.
115. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C et al. (1997). MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221-5225.
116. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. (2001). Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 61: 4985-4989.
117. Torres J, Rodriguez J, Myers MP, Valiente M, Graves JD, Tonks NK et al. (2003). Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 278: 30652-30660.
118. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
119. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156.
120. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. (2007). Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67: 10343-10350.
121. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. (2001). Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276: 48627-48630.
122. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. (2000). Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018.
123. Vermeij J, Teugels E, Bourgain C, Xiangming J, in't Veld P, Ghislain V et al. (2008). Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 8: 3.
124. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ et al. (2007). Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569.
125. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275.
126. Wang SI, Parsons R, Ittmann M. (1998). Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4: 811-815.
127. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D et al. (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183-4186.
128. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. (2007). NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139.
129. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamguney T et al. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9: 271-279.
130. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
131. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
132. Yao D, Alexander CL, Quinn JA, Chan WC, Wu H, Greenhalgh DA. (2008). Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21WAF-induced differentiation triggered by GSK3{beta} inactivation and reduced AKT activity. J Cell Sci 121: 1758-1769.
133. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R et al. (2002). Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99: 1455-1460.
134. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628.
135. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. (2003a). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.
136. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. (2003b). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581.
137. Zhao L, Vogt PK. (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105: 2652-2657.
138. Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M et al. (2001). Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358: 210-211.
139. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A et al. (2002). PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161: 439-447.
140. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C. (2000). Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 9: 765-768.